先看重点
在这项纳入随机试验的个体患者数据荟萃分析中,自测血压使12个月时门诊收缩压下降(-3.2 mmHg,95%置信区间-4.9至-1.6),但单纯自测没有明确效果(-1.0 mmHg;95%置信区间-3.3至1.2)。各试验间异质性仍然很大,具体到某一场景,效果可能不同。
证据类型
证据综述
解读依据
公开摘要
阅读重点
方法与适用范围
研究在问什么
居家自测血压似乎能降低高血压患者的血压,但应如何实施、哪些人获益最多仍不清楚。作者汇总各试验的个体患者数据,评估自测对血压以及血压达标比例的影响。
研究了谁,如何研究
对比较自测血压与不自测的高血压患者随机试验做系统综述和个体患者数据(IPD)荟萃分析。2016年6月检索了Medline、Embase和Cochrane图书馆,由两名评价者独立评估入选资格。在2,846篇文献中,36项试验符合条件,其中25项提供了IPD(含1项未发表研究)。12个月时的主要结局为门诊或动态血压均值的变化和血压达标比例,数据来自19项可能研究中的15项(8,292名随机受试者中的7,138人,86%)。
主要发现
以下为作者报告的结果。数字须连同人群和不确定性一起阅读。
- 1总体上,自测使12个月时门诊收缩压比常规诊疗更低(-3.2 mmHg;95%置信区间-4.9至-1.6)。
- 2效果取决于是否有配套支持:单纯自测没有明确效果(-1.0 mmHg;95%置信区间-3.3至1.2),与强化支持联合时降低6.1 mmHg(95%置信区间-9.0至-3.2)。
- 3服用降压药较少、基线收缩压较高(最高至170 mmHg)的人获益最大。按性别和大多数合并症分层未见差异。
- 44项几乎没有联合干预的试验(1,478名患者)中,自测与门诊收缩压(-0.2 mmHg;95%置信区间-2.2至1.8)或动态收缩压(1.1 mmHg;95%置信区间-0.3至2.5)降低均无关联。舒张压结果类似。
局限与不确定性
- 1作者指出仍存在明显的异质性,至少部分来自入选标准、自测方案和目标血压的不同。
- 212个月的动态血压数据只来自4项试验,且都几乎没有联合干预。
- 3主要结局数据只覆盖19项可能研究中的15项,有些试验缺失。
- 4摘要除药物调整、教育和生活方式咨询等例子外,没有界定强化支持的具体内容。
对日常健康的启示
只靠自己测血压,很可能不会使血压下降;获益出现在读数被医生、药师或患者本人用来调整用药,或与教育、生活方式咨询结合时。可以问问医生,你的家庭血压数值将如何被使用。不要自行调整药物。
如何联系自己的数据
家用血压计正是本文所讨论的对象。请使用同一台经验证的血压计,保持手臂、姿势和测量时间一致,并把变化趋势带给医生,而不是对单次数值做出反应。
如何理解这类证据
先看纳入了哪些设计、检索与偏倚评估如何完成,以及检索截止日期;发表新不代表底层证据都是最新的。
作者的结构化摘要 English
以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。
Background
Self-monitoring of blood pressure (BP) appears to reduce BP in hypertension but important questions remain regarding effective implementation and which groups may benefit most. This individual patient data (IPD) meta-analysis was performed to better understand the effectiveness of BP self-monitoring to lower BP and control hypertension.
Methods and findings
Medline, Embase, and the Cochrane Library were searched for randomised trials comparing self-monitoring to no self-monitoring in hypertensive patients (June 2016). Two reviewers independently assessed articles for eligibility and the authors of eligible trials were approached requesting IPD. Of 2,846 articles in the initial search, 36 were eligible. IPD were provided from 25 trials, including 1 unpublished study. Data for the primary outcomes-change in mean clinic or ambulatory BP and proportion controlled below target at 12 months-were available from 15/19 possible studies (7,138/8,292 [86%] of randomised participants). Overall, self-monitoring was associated with reduced clinic systolic blood pressure (sBP) compared to usual care at 12 months (-3.2 mmHg, [95% CI -4.9, -1.6 mmHg]). However, this effect was strongly influenced by the intensity of co-intervention ranging from no effect with self-monitoring alone (-1.0 mmHg [-3.3, 1.2]), to a 6.1 mmHg (-9.0, -3.2) reduction when monitoring was combined with intensive support. Self-monitoring was most effective in those with fewer antihypertensive medications and higher baseline sBP up to 170 mmHg. No differences in efficacy were seen by sex or by most comorbidities. Ambulatory BP data at 12 months were available from 4 trials (1,478 patients), which assessed self-monitoring with little or no co-intervention. There was no association between self-monitoring and either lower clinic or ambulatory sBP in this group (clinic -0.2 mmHg [-2.2, 1.8]; ambulatory 1.1 mmHg [-0.3, 2.5]). Results for diastolic blood pressure (dBP) were similar. The main limitation of this work was that significant heterogeneity remained. This was at least in part due to different inclusion criteria, self-monitoring regimes, and target BPs in included studies.
Conclusions
Self-monitoring alone is not associated with lower BP or better control, but in conjunction with co-interventions (including systematic medication titration by doctors, pharmacists, or patients; education; or lifestyle counselling) leads to clinically significant BP reduction which persists for at least 12 months. The implementation of self-monitoring in hypertension should be accompanied by such co-interventions.
来源与署名
Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis.
Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP, Earle K, George J, Godwin M, Green BB, Hebert P, Hobbs FDR, Kantola I, Kerry SM, Leiva A, Magid DJ, Mant J, Margolis KL, McKinstry B, McLaughlin MA, Omboni S, Ogedegbe O, Parati G, Qamar N, Tabaei BP, Varis J, Verberk WJ, Wakefield BJ, McManus RJ.
PLoS medicine · 2017-09-19
DOI: 10.1371/journal.pmed.1002389 ↗PubMed · 28926573 ↗Europe PMC · 记录的开放许可: cc by ↗摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。
MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅
来源核验日期 2026-11-01
实用健康指南
放在一起读
昼夜活动节律紊乱与更高的死亡风险相关(109,365人)
在7项观察性研究、共109,365名参与者中,昼夜活动对比较弱(相对振幅较低)与更高的心血管死亡风险(风险比[HR]1.50,95%置信区间1.13至1.98)和全因死亡风险(HR 1.46,95%置信区间1.27至1.68)相关。证据基础小,又是观察性的,不能说明改善节律就能降低风险,疾病本身也可能扰乱节律。
Journal of the American Heart Association
五类运动都降低了静息血压,等长训练降幅最大
汇总270项随机试验、共15,827名参与者的结果,有氧、抗阻、联合、间歇和等长训练与无干预对照组相比都降低了静息血压(各P<0.001),其中等长训练降幅最大:收缩压下降8.24 mm Hg,舒张压下降4.00 mm Hg。各方式之间的排序部分来自间接比较,各试验也不尽相同,所以排序不是个人的运动处方。
British Journal of Sports Medicine
盐替代品使中国农村高危人群的卒中、主要心血管事件和死亡率下降
在中国农村600个村庄、20,995名有卒中史或年龄在60岁及以上且有高血压的人中,使用盐替代品(氯化钠75%、氯化钾25%)的卒中发生率低于普通盐:平均随访4.74年,每1000人年29.14次对33.65次(率比0.86,95%置信区间0.77至0.96;P=0.006)。死亡也更低(率比0.88),严重高钾血症事件没有显著增多,但试验为开放标签设计,且在中国农村开展。
The New England Journal of Medicine
智能手表脉搏不规则提醒较少见,做贴片检查者34%确有房颤
在419,297名没有已知心房颤动(房颤)的苹果手表用户中,0.52%收到脉搏不规则提醒;返还可用心电贴片的450人中,34%确认有房颤(97.5%置信区间29至39)。提醒发出时恰有贴片记录的,通知的阳性预测值为0.84(95%置信区间0.76至0.92),但收到提醒者中仅20.8%返还了贴片,没有收到提醒的人未被监测,所以手表没有提醒并不能排除房颤。
The New England Journal of Medicine

